B Cells (B Lymphocytes) is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
B cells (B lymphocytes) are adaptive immune cells that play critical roles in humoral immunity through antibody production. While traditionally studied in peripheral immunology, emerging research reveals important roles for B cells and humoral immunity in neurodegenerative diseases.
B cells are produced and matured in the bone marrow, where they develop antigen receptors (B cell receptors/BCRs). Upon encountering antigen, B cells differentiate into plasma cells (antibody-secreting cells) and memory B cells.
- CD19 - pan-B cell marker
- CD20 - therapeutic target (rituximab)
- CD21 - complement receptor
- CD27 - memory B cell marker
- IgM/IgD - surface immunoglobulin
¶ Antibody Production
- Neutralizing antibodies - block pathogens and toxins
- Opsonizing antibodies - enhance phagocytosis
- Complement-activating antibodies - initiate complement cascade
B cells present antigens to T cells via MHC class II, bridging innate and adaptive immunity.
B cells secrete regulatory cytokines including:
- IL-6 - inflammation and B cell differentiation
- IL-10 - anti-inflammatory effects
- TNF-α - pro-inflammatory signaling
- IFN-γ - Th1 polarization
- Patients show elevated autoantibodies against neural antigens
- Anti-amyloid antibodies (natural and therapeutic)
- Anti-tau antibodies in cerebrospinal fluid
- Antibodies to neuronal surface antigens
- B cells found in AD brain parenchyma
- Perivascular B cell aggregates in leptomeninges
- Tertiary lymphoid structures in AD dura
- Anti-Aβ antibodies (aducanumab, lecanemab, donanemab)
- Passive immunization strategies
- B cell depletion (rituximab) trials
- Elevated anti-α-synuclein antibodies
- Autoantibodies against dopamine neurons
- Cross-reactive antibodies (molecular mimicry)
- Altered B cell repertoire in PD
- Elevated BAFF (B cell activating factor)
- Intrathecal IgG synthesis
¶ Antibody Involvement
- Anti-neuronal antibodies in ALS patients
- Antibodies against voltage-gated calcium channels
- Anti-GM1 antibodies (motor neuron reactivity)
- Altered B cell subsets in ALS
- Elevated serum IgG levels
- CSF oligoclonal bands in some patients
While primarily demyelinating, MS shares features with neurodegeneration:
- B cell infiltration in lesions
- Oligoclonal IgG bands in CSF
- Anti-myelin antibodies
- B cell depletion therapies effective (ocrelizumab)
- Systemic B cells - produce serum antibodies
- CNS-infiltrating B cells - localized immune response
- Meningeal B cells - tertiary lymphoid organs
¶ Antibody Transport
- IgG transport across blood-brain barrier via FcRn receptor
- Differential IgG subclass distribution in CSF
- Polyclonal vs monoclonal antibody patterns
| Drug |
Target |
Application |
| Rituximab |
CD20 |
Deplete B cells |
| Ocrelizumab |
CD20 |
MS, trials in AD |
| Belimumab |
BAFF |
Autoimmune |
| Abciximab |
Glycoprotein IIb/IIIa |
Neuroprotection |
- BAFF inhibition (belimumab, tabalumab)
- IL-6 receptor blockade (tocilizumab)
- Costimulatory blockade
The study of B Cells (B Lymphocytes) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Baker CA, et al. B cells in Alzheimer's disease. Nat Rev Immunol. 2022
- Wang J, et al. B cells and autoantibodies in Parkinson's disease. J Neuroinflammation. 2021
- Fiala M, et al. B cells in ALS. Neurology. 2020
- Lund H, et al. B cell therapies in multiple sclerosis. Nat Rev Neurol. 2023
- Balkema GW, et al. Immunotherapy for Alzheimer's disease. Nat Rev Drug Discov. 2021
- Peluso MJ, et al. CNS humoral immunity in neurodegeneration. Trends Neurosci. 2022